Alone laser versus bevacizumab plus laser for diffuse diabetic macular edema (ALBA randomized trial).

ABSTRACT:

Purpose

To report the 12-month results of laser (treatment G1) versus intravitreal bevacizumab combined with laser (treatment G2) in patients with diffuse diabetic macular edema (DME).

Methods

In this single-center randomized independent controlled trial, 32 patients were randomized to G1 (n = 15) or G2 (n = 17). In G1, laser was given at baseline and then pro re nata (PRN). In G2, three intravitreal bevacizumab (1.25 mg) injections were given once every 6 weeks, then laser and then PRN. Analysis was performed by treatment as administered. This study was registered in clinicaltrials.gov as NCT01572350 and EU Clinical Trial Registry as 2009-014654-15.

Results

G2 was superior to G1 improving best corrected visual acuity (BCVA) with respect baseline (+8.0 v

SUBMITTER: Pareja-Rios A 

PROVIDER: S-EPMC7812399 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature